Fulton Bank N.A. Purchases 3,515 Shares of GlaxoSmithKline plc (GSK)

Fulton Bank N.A. raised its position in GlaxoSmithKline plc (NYSE:GSK) by 4.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,269 shares of the pharmaceutical company’s stock after purchasing an additional 3,515 shares during the quarter. Fulton Bank N.A.’s holdings in GlaxoSmithKline plc were worth $3,056,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. 1st Global Advisors Inc. grew its holdings in GlaxoSmithKline plc by 0.4% during the second quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after purchasing an additional 19 shares during the period. Carroll Financial Associates Inc. grew its holdings in GlaxoSmithKline plc by 0.4% during the second quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock worth $374,000 after purchasing an additional 35 shares during the period. King Luther Capital Management Corp grew its holdings in GlaxoSmithKline plc by 1.0% during the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after purchasing an additional 55 shares during the period. First National Bank of Omaha grew its holdings in GlaxoSmithKline plc by 0.3% during the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock worth $827,000 after purchasing an additional 57 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in GlaxoSmithKline plc by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 64 shares during the period. Institutional investors own 9.31% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 27th. TheStreet downgraded shares of GlaxoSmithKline plc from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Argus restated a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline plc in a research report on Thursday, August 31st. Zacks Investment Research downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Bank of America Corporation downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “neutral” rating in a research report on Thursday. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $44.33.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/fulton-bank-n-a-has-3-06-million-holdings-in-glaxosmithkline-plc-gsk.html.

Shares of GlaxoSmithKline plc (NYSE GSK) traded down 0.79% during mid-day trading on Friday, hitting $36.31. 3,603,116 shares of the company traded hands. The firm’s 50 day moving average price is $40.48 and its 200-day moving average price is $41.49. GlaxoSmithKline plc has a 1-year low of $36.20 and a 1-year high of $44.54. The stock has a market capitalization of $88.74 billion, a PE ratio of 35.18 and a beta of 1.03.

GlaxoSmithKline plc (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities research analysts forecast that GlaxoSmithKline plc will post $2.89 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a $0.5037 dividend. This is a boost from GlaxoSmithKline plc’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.51%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline plc’s dividend payout ratio (DPR) is currently 162.30%.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline plc (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply